Unique, dedicated global capabilities support our strategy:
- Worldwide commercial and development organization in more than 55 countries, with a decade of experience and approximately 7,000 employees dedicated to oncology research and development.
- Vibrant portfolio of innovative medicines with a focus on oncologic, hematologic and targeted diseases.
- Internal capabilities dedicated to developing companion diagnostics that help physicians make the best treatment decisions for their patients.
